Abstract 494P
Background
The study aimed to assess the effects of a modified electric field patch operation method on scalp adverse reactions in glioblastoma patients undergoing tumor treating fields (TTFields).
Methods
A total of 73 glioblastoma patients who received TTFields between May 2019 and July 2022 were included in the study. The control group consisted of 36 patients treated with the conventional electric field patch operation method before April 2021, while the modified group included 37 patients treated after May 2021 using an improved technique for adhesion and removal of the electric field patch. The study conducted a comparison between two groups regarding the incidence of adverse scalp reactions and compliance with TTFields.
Results
The modified group exhibited significantly lower rates of scalp pruritus (P=0.0246), contact dermatitis (P=0.0253), and skin ulceration (P=0.0299) compared to the control group. Additionally, compliance with TTFields was notably higher in the modified group (81.1%) than in the control group (52.8%) with a statistically significant difference (P=0.0101). Furthermore, the incidence of adverse scalp reactions displayed seasonal variability, with the highest rates observed in summer (56.16%) and the lowest in winter (8.22%). Following the implementation of the adjusted electric field patch operation technique, a notable decrease in the incidence of adverse scalp reactions during the summer (P=0.0002), autumn (P=0.0411), and spring (P=0.0342) seasons was observed.
Conclusions
The utilization of this modified method has demonstrated efficacy in mitigating scalp adverse reactions, minimizing treatment disruptions, and enhancing adherence to TTFields therapy among patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
469P - Detection of circulating tumor DNA (ctDNA) in cerebrospinal fluid (CSF) in patients with glioblastoma treated in phase I clinical trial
Presenter: Marie Porte
Session: Poster session 16
470P - Mitochondrial ribosomal proteins (MRPs) in glioblastoma multiforme: Omics approach
Presenter: Jehad Yasin
Session: Poster session 16
471P - PTEN alteration as a predictor of second-line efficacy in patients with recurrent IDHwt-glioblastoma
Presenter: Eugenia Cella
Session: Poster session 16
472P - Comprehensive quinomics assessment of BPM31510IV treatment in advanced glioblastoma multiforme patients
Presenter: Seema Nagpal
Session: Poster session 16
473P - A novel machine learning (ML) model integrating clinical and molecular data to predict response to second-line treatment in recurrent IDHwt-glioblastoma (rGBM)
Presenter: Maurizio Polano
Session: Poster session 16
474P - Potassium inward rectifier channel subfamily J member 11 mRNA expression in glioma and its significance in predicting prognosis and chemotherapy sensitivity
Presenter: kaijia zhou
Session: Poster session 16
Resources:
Abstract
475P - Optimising genomic testing for patients with central nervous system (CNS) tumours using oxford nanopore technology
Presenter: Alona Sosinsky
Session: Poster session 16
476P - The role of androgen receptor expression and epigenetic regulation in adult-type diffuse gliomas
Presenter: VINCENZO DI NUNNO
Session: Poster session 16
477P - ENHO's protective role in lower grade glioma
Presenter: Osama Younis
Session: Poster session 16